Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported ...
Some of the information was easy to find, others difficult, and some of the results were surprising ...
Federal government said it is committed to the implementation of stricter, more organized drone regulations to balance innovation with national security. This came as stakeholders at the 6th Dronetecx ...